RIS Article 180: Additional Documents for Foreign-Manufactured Medical Devices

1. Key takeaways

When a medical device manufactured outside Mexico is filed for sanitary registration with COFEPRIS, the applicant must satisfy not only the documentary requirements that apply to domestically manufactured products, but also a set of additional requirements established by Article 180 of the Reglamento de Insumos para la Salud (RIS). For foreign-manufactured devices, four additional documents must be appended to the dossier: a certificate of free sale or equivalent document issued by the competent authority of the country of origin; a letter of authorisation from the manufacturer (required whenever the product is not manufactured by the parent company, plant or laboratory applying for registration); a certificate of good manufacturing practice issued by the competent authority of the country of origin; and the original certificate of analysis issued on the manufacturing company letterhead and signed by its responsible chemist. Understanding how these four items interact with the baseline dossier under Article 179 is the single most important step in assembling a complete foreign-manufacturer submission, because a missing or wrongly issued document at this layer is one of the most common grounds for a deficient-file notice.

• Certificate of free sale or equivalent, issued by the health authority of the country of origin.
• Manufacturer authorisation letter, triggered when the product is not made by the applying parent company, plant or laboratory.
• Good manufacturing practice certificate issued by the competent authority of the country of origin.
• Original certificate of analysis on manufacturing company letterhead, signed by the responsible chemist.

2. Legal basis

The additional requirements for foreign-manufactured products rest on a small but precise body of regulation. Article 180 of the RIS, introduced through the amendment order published in the Diario Oficial de la Federacion on 24 April 2026, enumerates the four additional documents summarised above. Article 179 sets out the baseline documentary requirements that apply to both domestic and foreign manufacture, and remains fully applicable even when the Article 180 annexes are provided. Article 153 requires that applications for sanitary authorisation be made on the official form and accompanied by the documents listed in the regulation. Finally, the low-risk protocol published on 15 July 2025 addresses imported products and confirms that, where the applicant is not the manufacturing parent company, a letter of authorisation must be submitted. The table below consolidates these sources.

3. Expert insights

Insight 1: the four items are additional, not exhaustive. The wording of Article 180 reads that these documents must be provided in addition to the previous documents, a point expressed in the Spanish text as ademas de los documentos anteriores. In other words, the baseline documentation of Article 179 remains fully required. A dossier that contains only the four foreign-manufacture annexes, however complete they may be, does not satisfy the regulation. Preparing the two layers separately, and checking each layer against its own list before filing, is the reliable way to avoid a deficiency notice on this ground.

Insight 2: the certificate of free sale must come from a competent authority. Item I of Article 180 requires a certificate of free sale or equivalent document issued by the health authority of the country of origin. Statements issued by industry associations, chambers of commerce or the exporting company itself do not meet this wording. Applicants should verify the identity of the issuing body on the face of the certificate before the document is legalised and translated, because a certificate from the wrong issuer cannot be cured by a supplementary letter at a later stage of the review.

Insight 3: the authorisation letter is triggered by non-parent-company manufacture. Item II of Article 180 sets out a very specific trigger: the letter is required when the product is not manufactured by the parent company, plant or laboratory applying for registration. Where manufacturing is outsourced to a third party, the trigger is necessarily met and the letter must be included. Applicants who own several plants should read this trigger carefully against their own corporate structure, since the question of which entity counts as the applying company determines whether the letter is needed at all.

Insight 4: the GMP certificate is also subject to the competent-authority requirement. Item III of Article 180 requires a certificate of good manufacturing practice issued by the health authority of the country of origin. This should not be conflated with quality system evidence. The GMP certificate under Article 180 and the quality management system documentation, such as ISO 13485 certification or MDSAP participation, travel on two separate tracks: the former is a statutory document required by Article 180, while the latter serves as quality system evidence in its own right. Holding one does not substitute for the other.

Insight 5: the certificate of analysis carries signature and letterhead requirements. Item IV of Article 180 requires an original document, issued on the letterhead of the manufacturing company and signed by its responsible chemist. For device manufacturers that do not operate a chemist function, this is frequently the most difficult item to arrange in practice, and it is a practical estimate that lead time for aligning the signature arrangement should be built into the project plan. The signatory arrangement, the letterhead format and the delivery of the original should be confirmed with the manufacturer well before the dossier is assembled. Any element of this item that cannot be confirmed at filing time should be treated as pending verification until the original document is in hand.

4. Practical recommendations

• Maintain two parallel checklists, one for the Article 179 baseline documents and one for the Article 180 additional documents, and tick them off separately so that neither layer is neglected.
• Apply for the certificate of free sale and the GMP certificate from the competent authority of the country of origin well in advance, paying attention to their validity periods and the issuing timeframes.
• In any outsourced manufacturing scenario, attach the authorisation letter as a matter of course, stating clearly in the letter the scope of products covered and the term of the authorisation.
• Agree with the manufacturer in advance on the signatory of the certificate of analysis, the letterhead format and the courier arrangement for delivering the original document.
• Arrange certified translation into Spanish by a perito traductor for every document not originally in Spanish; documents in Chinese in particular require a Spanish-language version prepared through this channel.

5. Verification checklist

• □ The Article 179 baseline documentation is complete.
• □ The certificate of free sale was issued by the competent authority of the country of origin and is within its validity period.
• □ Where manufacturing is outsourced, the authorisation letter has been attached.
• □ The GMP certificate was issued by the competent authority of the country of origin.
• □ The certificate of analysis is an original, on company letterhead, signed by the responsible chemist.
• □ All documents not in Spanish have undergone certified translation.

Legal information verified as of 28 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Mexican market. Our team manages COFEPRIS registrations and equivalence (equivalencia) reviews, coordinates third-party authorised centre routes, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com